UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

UCLA Institute of Urologic Oncology



PDF | Flipbook

Our Mission

Why Choose the UCLA Institute of Urologic Oncology?

Mission Statement

Arnold Chin, MD, PhD. UCLA Institute of Urologic OncologyThe UCLA Institute of Urologic Oncology (the "IUO") was established in the fall of 2008 as an interdisciplinary collaboration, bringing together world-renown physicians and scientists from the UCLA Departments of Urologic Oncology, Medical Oncology, Radiation Oncology and Pathology, to work together as a team to personalize patient care and to develop state-of-the-art technologies and revolutionary treatments for kidney, prostate, bladder and testicular cancers. We developed this centralized structure to provide our patients with convenient interdisciplinary care (sequential appointments on the same day with providers from two disciplines) as well as multi-disciplinary care in a single appointment.

Prostate, kidney, bladder and testicular cancers strike nearly 400,000 Americans each year and lead to approximately 50,000 deaths.  The IUO harnesses the collective expertise and wisdom of specialists in urologic and medical oncology, diagnostic and interventional radiology, pathology, nursing, basic sciences and clinical trials.


The IUO focuses the comprehensive resources available at UCLA on personalized, patient-centered treatment of urologic cancers and the development and delivery of new therapies. Patients can conveniently access the various specialists involved in their care, thereby simplifying the decision-making process for preferred treatment and improving their overall medical care.


This integrated approach allows experts from related disciplines to collaborate more efficiently and effectively to bring to patients the most promising advances in disease-centered, multi-specialty diagnosis and medical and surgical treatments-including molecular pathology, targeted therapies, chemotherapy, immunotherapy, radiation therapy, and minimally invasive and ablative surgery.


UCLA has been a pioneer in the multidisciplinary, translational approach to care, including targeted therapies; the development of novel, minimally invasive cancer surgeries and reconstructive surgical techniques offering improved quality of life; and the development of molecularly targeted drugs. Avastin, Sutent, Nexavar, Toricel, Afinitor, Abiraterone, MDR 3100, Herceptin, and Gleevec, among others, were developed in large part based on research conducted in the clinics and laboratories of UCLA's Jonsson Comprehensive Cancer Center. Such leading-edge work to develop new, personalized, less toxic, and more-effective therapies for urologic cancers will be done within the IUO.


The IUO harnesses the collective expertise of specialists in urologic and medical oncology, diagnostic and interventional radiology, pathology, nursing, basic sciences, and clinical trials to advance the most innovative and integrated approaches to the prevention, diagnosis, and treatment of urologic cancers. Patients benefit from the combined experience of these doctors, who often treat the most complicated urologic cancer cases.


UCLA Rated One of the Top Hospitals in the Nation